Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Superior skin cancer classification by the combination of human and artificial intelligence.

Hekler A, Utikal JS, Enk AH, Hauschild A, Weichenthal M, Maron RC, Berking C, Haferkamp S, Klode J, Schadendorf D, Schilling B, Holland-Letz T, Izar B, von Kalle C, Fröhling S, Brinker TJ; Collaborators.

Eur J Cancer. 2019 Oct;120:114-121. doi: 10.1016/j.ejca.2019.07.019. Epub 2019 Sep 10.

2.

Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks.

Maron RC, Weichenthal M, Utikal JS, Hekler A, Berking C, Hauschild A, Enk AH, Haferkamp S, Klode J, Schadendorf D, Jansen P, Holland-Letz T, Schilling B, von Kalle C, Fröhling S, Gaiser MR, Hartmann D, Gesierich A, Kähler KC, Wehkamp U, Karoglan A, Bär C, Brinker TJ; Collabrators.

Eur J Cancer. 2019 Sep;119:57-65. doi: 10.1016/j.ejca.2019.06.013. Epub 2019 Aug 14.

3.

Deep neural networks are superior to dermatologists in melanoma image classification.

Brinker TJ, Hekler A, Enk AH, Berking C, Haferkamp S, Hauschild A, Weichenthal M, Klode J, Schadendorf D, Holland-Letz T, von Kalle C, Fröhling S, Schilling B, Utikal JS.

Eur J Cancer. 2019 Sep;119:11-17. doi: 10.1016/j.ejca.2019.05.023. Epub 2019 Aug 8.

4.

Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis.

Afshar-Oromieh A, Vollnberg B, Alberts I, Bähler A, Sachpekidis C, Dijkstra L, Haupt F, Boxler S, Gross T, Holland-Letz T, Thalmann G, Heverhagen J, Rominger A, Härmä K, Maurer MH.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2289-2297. doi: 10.1007/s00259-019-04438-w. Epub 2019 Jul 27.

PMID:
31350604
5.

Lymph node involvement in treatment-naïve prostate cancer patients - correlation of PSMA-PET/CT imaging and Roach formula in 280 men in the Radiotherapeutic management.

Koerber SA, Stach G, Kratochwil C, Haefner MF, Rathke H, Herfarth K, Kopka K, Holland-Letz T, Choyke PL, Will L, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2019 Jul 13. pii: jnumed.119.227637. doi: 10.2967/jnumed.119.227637. [Epub ahead of print]

PMID:
31302638
6.

Pathologist-level classification of histopathological melanoma images with deep neural networks.

Hekler A, Utikal JS, Enk AH, Berking C, Klode J, Schadendorf D, Jansen P, Franklin C, Holland-Letz T, Krahl D, von Kalle C, Fröhling S, Brinker TJ.

Eur J Cancer. 2019 Jul;115:79-83. doi: 10.1016/j.ejca.2019.04.021. Epub 2019 May 23.

7.

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 May;113:47-54. doi: 10.1016/j.ejca.2019.04.001. Epub 2019 Apr 10.

8.

Impact of sialendoscopy on improving health related quality of life in patients suffering from radioiodineinduced xerostomia.

Bulut OC, Haufe S, Hohenberger R, Hein M, Kratochwil C, Rathke H, Plinkert PK, Baumann I, Holland-Letz T, Haberkorn U, Flechsig P.

Nuklearmedizin. 2018 Aug;57(4):160-167. doi: 10.3413/Nukmed-0964-18-03. Epub 2018 Aug 20.

PMID:
30125928
9.

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2045-2054. doi: 10.1007/s00259-018-4079-z. Epub 2018 Jul 7.

10.

Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs.

Wünsche P, Eckert ESP, Holland-Letz T, Paruzynski A, Hotz-Wagenblatt A, Fronza R, Rath T, Gil-Farina I, Schmidt M, von Kalle C, Klein C, Ball CR, Herbst F, Glimm H.

Cell Stem Cell. 2018 Jul 5;23(1):132-146.e9. doi: 10.1016/j.stem.2018.06.003.

11.

68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.

Koerber SA, Will L, Kratochwil C, Haefner MF, Rathke H, Kremer C, Merkle J, Herfarth K, Kopka K, Choyke PL, Holland-Letz T, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2018 Jul 5. pii: jnumed.118.211086. doi: 10.2967/jnumed.118.211086. [Epub ahead of print]

12.

Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.

Flechsig P, Rastgoo R, Kratochwil C, Martin O, Holland-Letz T, Harms A, Kauczor HU, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2018 Dec;20(6):1044-1052. doi: 10.1007/s11307-018-1196-9.

PMID:
29679299
13.

Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals.

Cao X, Tang Q, Holland-Letz T, Gündert M, Cuk K, Schott S, Heil J, Golatta M, Sohn C, Schneeweiss A, Burwinkel B.

Int J Mol Sci. 2018 Mar 19;19(3). pii: E900. doi: 10.3390/ijms19030900.

14.

Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT.

Afshar-Oromieh A, Sattler LP, Steiger K, Holland-Letz T, da Cunha ML, Mier W, Neels O, Kopka K, Weichert W, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1179-1187. doi: 10.1007/s00259-018-3965-8. Epub 2018 Mar 1.

PMID:
29497802
15.

Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.

Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, Holland-Letz T, Utikal J, Schadendorf D, Neumaier M.

Clin Chem. 2018 May;64(5):830-842. doi: 10.1373/clinchem.2017.281543. Epub 2018 Feb 26.

16.

Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.

Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Sep;59(9):1373-1379. doi: 10.2967/jnumed.117.200220. Epub 2018 Jan 25.

17.

Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.

Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Burwinkel B.

Breast Cancer Res Treat. 2018 May;169(1):69-82. doi: 10.1007/s10549-018-4666-5. Epub 2018 Jan 16.

PMID:
29340881
18.

Role of CT Density in PET/CT-Based Assessment of Lymphoma.

Flechsig P, Walker C, Kratochwil C, König L, Iagura A, Moltz J, Holland-Letz T, Kauczor HU, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2018 Aug;20(4):641-649. doi: 10.1007/s11307-017-1155-x.

PMID:
29270848
19.

Parametric modeling and optimal experimental designs for estimating isobolograms for drug interactions in toxicology.

Holland-Letz T, Gunkel N, Amtmann E, Kopp-Schneider A.

J Biopharm Stat. 2018;28(4):763-777. doi: 10.1080/10543406.2017.1397005. Epub 2017 Nov 27.

PMID:
29173022
20.

Highly efficient destruction of squamous carcinoma cells of the head and neck by photochemical internalization of Ranpirnase.

Liebers N, Holland-Letz T, Welschof M, Høgset A, Jäger D, Arndt MAE, Krauss J.

J Exp Ther Oncol. 2017 Nov;12(2):113-120.

PMID:
29161778
21.

The challenge of mapping the human connectome based on diffusion tractography.

Maier-Hein KH, Neher PF, Houde JC, Côté MA, Garyfallidis E, Zhong J, Chamberland M, Yeh FC, Lin YC, Ji Q, Reddick WE, Glass JO, Chen DQ, Feng Y, Gao C, Wu Y, Ma J, Renjie H, Li Q, Westin CF, Deslauriers-Gauthier S, González JOO, Paquette M, St-Jean S, Girard G, Rheault F, Sidhu J, Tax CMW, Guo F, Mesri HY, Dávid S, Froeling M, Heemskerk AM, Leemans A, Boré A, Pinsard B, Bedetti C, Desrosiers M, Brambati S, Doyon J, Sarica A, Vasta R, Cerasa A, Quattrone A, Yeatman J, Khan AR, Hodges W, Alexander S, Romascano D, Barakovic M, Auría A, Esteban O, Lemkaddem A, Thiran JP, Cetingul HE, Odry BL, Mailhe B, Nadar MS, Pizzagalli F, Prasad G, Villalon-Reina JE, Galvis J, Thompson PM, Requejo FS, Laguna PL, Lacerda LM, Barrett R, Dell'Acqua F, Catani M, Petit L, Caruyer E, Daducci A, Dyrby TB, Holland-Letz T, Hilgetag CC, Stieltjes B, Descoteaux M.

Nat Commun. 2017 Nov 7;8(1):1349. doi: 10.1038/s41467-017-01285-x.

22.

Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer.

Cosenza MR, Cazzola A, Rossberg A, Schieber NL, Konotop G, Bausch E, Slynko A, Holland-Letz T, Raab MS, Dubash T, Glimm H, Poppelreuther S, Herold-Mende C, Schwab Y, Krämer A.

Cell Rep. 2017 Aug 22;20(8):1906-1920. doi: 10.1016/j.celrep.2017.08.005.

23.

Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1781. doi: 10.1007/s00259-017-3763-8. No abstract available.

PMID:
28656360
24.

68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.

J Nucl Med. 2017 Dec;58(12):1949-1955. doi: 10.2967/jnumed.116.185033. Epub 2017 Jun 21.

25.

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. doi: 10.1007/s00259-017-3711-7. Epub 2017 May 12. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1781.

26.

Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.

Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL.

J Nucl Med. 2017 Nov;58(11):1805-1810. doi: 10.2967/jnumed.116.189233. Epub 2017 May 4. Erratum in: J Nucl Med. 2019 Apr;60(4):554.

27.

Dissecting and modeling the emergent murine TEC compartment during ontogeny.

Brunk F, Michel C, Holland-Letz T, Slynko A, Kopp-Schneider A, Kyewski B, Pinto S.

Eur J Immunol. 2017 Jul;47(7):1153-1159. doi: 10.1002/eji.201747006. Epub 2017 May 22.

28.

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.

Afshar-Oromieh A, Haberkorn U, Zechmann C, Armor T, Mier W, Spohn F, Debus N, Holland-Letz T, Babich J, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):950-959. doi: 10.1007/s00259-017-3665-9. Epub 2017 Mar 9.

29.

Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.

Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M.

Neuro Oncol. 2017 Sep 1;19(9):1255-1262. doi: 10.1093/neuonc/now290.

30.

The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.

Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, Kopka K, Haberkorn U.

J Nucl Med. 2017 May;58(5):750-755. doi: 10.2967/jnumed.116.183483. Epub 2017 Jan 6.

31.

Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.

Giesel FL, Schneider F, Kratochwil C, Rath D, Moltz J, Holland-Letz T, Kauczor HU, Schwartz LH, Haberkorn U, Flechsig P.

J Nucl Med. 2017 Feb;58(2):282-287. doi: 10.2967/jnumed.116.179648. Epub 2016 Sep 22.

32.

DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.

Tang Q, Holland-Letz T, Slynko A, Cuk K, Marme F, Schott S, Heil J, Qu B, Golatta M, Bewerunge-Hudler M, Sutter C, Surowy H, Wappenschmidt B, Schmutzler R, Hoth M, Bugert P, Bartram CR, Sohn C, Schneeweiss A, Yang R, Burwinkel B.

Oncotarget. 2016 Sep 27;7(39):64191-64202. doi: 10.18632/oncotarget.11640.

33.

On the combination of c- and D-optimal designs: General approaches and applications in dose-response studies.

Holland-Letz T.

Biometrics. 2017 Mar;73(1):206-213. doi: 10.1111/biom.12545. Epub 2016 May 24.

PMID:
27218478
34.

miR-339-3p Is a Tumor Suppressor in Melanoma.

Weber CE, Luo C, Hotz-Wagenblatt A, Gardyan A, Kordaß T, Holland-Letz T, Osen W, Eichmüller SB.

Cancer Res. 2016 Jun 15;76(12):3562-71. doi: 10.1158/0008-5472.CAN-15-2932. Epub 2016 Apr 15.

35.

Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC.

Cieciera M, Kratochwil C, Moltz J, Kauczor HU, Holland Letz T, Choyke P, Mier W, Haberkorn U, Giesel FL.

Diagn Interv Radiol. 2016 May-Jun;22(3):201-6. doi: 10.5152/dir.2015.15304.

36.

Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer.

Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, Afshar-Oromieh A, Kopka K, Debus J, Haberkorn U, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1400-6. doi: 10.1007/s00259-016-3346-0. Epub 2016 Mar 14.

37.

Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.

Flechsig P, Choyke P, Kratochwil C, Warth A, Antoch G, Holland Letz T, Rath D, Eichwald V, Huber PE, Kauczor HU, Haberkorn U, Giesel FL.

Diagn Interv Radiol. 2016 Jan-Feb;22(1):35-9. doi: 10.5152/dir.2015.15220.

38.

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U.

J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20.

39.

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.

Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V.

Clin Cancer Res. 2015 Dec 15;21(24):5453-9. doi: 10.1158/1078-0432.CCR-15-0676. Epub 2015 Aug 19.

40.

Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.

Wagner NB, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, Pflugfelder A, Herpel E, Eubel J, Ikenberg K, Busch C, Holland-Letz T, Naeher H, Garbe C, Umansky V, Enk A, Utikal J, Gebhardt C.

Int J Cancer. 2015 Dec 1;137(11):2607-17. doi: 10.1002/ijc.29619. Epub 2015 Jul 14.

41.

Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells.

Walter D, Lier A, Geiselhart A, Thalheimer FB, Huntscha S, Sobotta MC, Moehrle B, Brocks D, Bayindir I, Kaschutnig P, Muedder K, Klein C, Jauch A, Schroeder T, Geiger H, Dick TP, Holland-Letz T, Schmezer P, Lane SW, Rieger MA, Essers MA, Williams DA, Trumpp A, Milsom MD.

Nature. 2015 Apr 23;520(7548):549-52. doi: 10.1038/nature14131. Epub 2015 Feb 18.

PMID:
25707806
42.

Fundamental properties of unperturbed haematopoiesis from stem cells in vivo.

Busch K, Klapproth K, Barile M, Flossdorf M, Holland-Letz T, Schlenner SM, Reth M, Höfer T, Rodewald HR.

Nature. 2015 Feb 26;518(7540):542-6. doi: 10.1038/nature14242. Epub 2015 Feb 11.

PMID:
25686605
43.

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20.

44.

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.

Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier W, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2015 Jun;17(3):313-8. doi: 10.1007/s11307-014-0795-3.

PMID:
25319765
45.

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients.

Baccelli I, Stenzinger A, Vogel V, Pfitzner BM, Klein C, Wallwiener M, Scharpff M, Saini M, Holland-Letz T, Sinn HP, Schneeweiss A, Denkert C, Weichert W, Trumpp A.

Oncotarget. 2014 Sep 30;5(18):8147-60.

46.

Optimal experimental designs for dose-response studies with continuous endpoints.

Holland-Letz T, Kopp-Schneider A.

Arch Toxicol. 2015 Nov;89(11):2059-68. doi: 10.1007/s00204-014-1335-2. Epub 2014 Aug 26.

47.

True four-dimensional analysis of thoracic aortic displacement and distension using model-based segmentation of computed tomography angiography.

Weber TF, Müller T, Biesdorf A, Wörz S, Rengier F, Heye T, Holland-Letz T, Rohr K, Kauczor HU, von Tengg-Kobligk H.

Int J Cardiovasc Imaging. 2014 Jan;30(1):185-94. doi: 10.1007/s10554-013-0307-6. Epub 2013 Oct 18.

PMID:
24135852
48.

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20. doi: 10.1007/s00259-013-2525-5. Epub 2013 Sep 27.

49.

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W.

Acta Neuropathol. 2013 Sep;126(3):443-51. doi: 10.1007/s00401-013-1156-z. Epub 2013 Aug 1.

50.

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.

Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K, Weichert W, Trumpp A.

Nat Biotechnol. 2013 Jun;31(6):539-44. doi: 10.1038/nbt.2576. Epub 2013 Apr 21.

PMID:
23609047

Supplemental Content

Loading ...
Support Center